Synapse - Raphael Steiner

Results (18)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab

Meeting Abstract

Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; more...
Blood (2024)

Fulltext@MSK | Save

Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases

Meeting Abstract

Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
Blood (2024)

Fulltext@MSK | Save

A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign

Meeting Abstract

Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
Blood (2024)

Fulltext@MSK | Save

Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis

Meeting Abstract

Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study

Meeting Abstract

Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
Blood (2024)

Fulltext@MSK | Save

Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis

Meeting Abstract

Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
Blood (2024)

Fulltext@MSK | Save

Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
Blood (2024)

Fulltext@MSK | Save

Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)